Iovance Biotherapeutics has granted inducement stock options covering 62,790 shares to nine new non-executive employees, effective October 16, 2025....

Mesoblast reported a sharp commercial acceleration for Ryoncil, its FDA‑approved mesenchymal stromal cell therapy for pediatric steroid‑refractory acute graft-versus-host...

Praxis Precision Medicines reported positive topline results from two Phase 3 studies in its Essential3 program for ulixacaltamide in...

Agios Pharmaceuticals will report third-quarter 2025 financial results and business highlights on October 30 via webcast, signaling a near-term...

BPGbio will present two posters at ESMO 2025 on its mitochondrial-targeting candidate BPM31510 in glioblastoma, alongside confirmation that the...

ANI Pharmaceuticals will deliver a late-breaking oral presentation of the NEW DAY clinical trial for ILUVIEN (fluocinolone acetonide 0.19...

RetinalGeniX Technologies has engaged Seer to pair ultra–ultra-ultra-high-resolution retinal imaging with deep, unbiased proteomic profiling to identify biomarkers for...

Rakovina Therapeutics will present new preclinical data on a series of AI-designed ATR inhibitors with central nervous system penetrance...

At first glance, it looks like a paradox: pharma companies pour billions into AI pilots, and yet the success...

Rezolute plans a concentrated investor relations push this fall, with management set to meet investors at the Maxim Growth...